Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Research & Development (2018 - 2025)

Inmune Bio's Research & Development history spans 8 years, with the latest figure at $4.9 million for Q3 2025.

  • For Q3 2025, Research & Development fell 51.46% year-over-year to $4.9 million; the TTM value through Sep 2025 reached $25.7 million, down 19.29%, while the annual FY2024 figure was $33.2 million, 63.6% up from the prior year.
  • Research & Development for Q3 2025 was $4.9 million at Inmune Bio, down from $5.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.1 million in Q3 2024 and bottomed at $2.5 million in Q1 2021.
  • The 5-year median for Research & Development is $5.8 million (2025), against an average of $5.8 million.
  • The largest annual shift saw Research & Development soared 394.35% in 2021 before it tumbled 51.75% in 2022.
  • A 5-year view of Research & Development shows it stood at $7.1 million in 2021, then crashed by 51.75% to $3.4 million in 2022, then skyrocketed by 76.16% to $6.0 million in 2023, then rose by 22.41% to $7.4 million in 2024, then tumbled by 33.54% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Research & Development are $4.9 million (Q3 2025), $5.8 million (Q2 2025), and $7.6 million (Q1 2025).